首页> 外文期刊>Veterinary Parasitology >Therapeutic efficacy of eprinomectin extended-release injection against induced infections of developing (fourth-stage larvae) and adult nematode parasites of cattle
【24h】

Therapeutic efficacy of eprinomectin extended-release injection against induced infections of developing (fourth-stage larvae) and adult nematode parasites of cattle

机译:依普诺菌素缓释注射液对牛的发育中(第四阶段幼虫)和成年线虫寄生虫感染的治疗作用

获取原文
获取原文并翻译 | 示例
           

摘要

The therapeutic efficacy of eprinomectin in an extended-release injection (ERI) formulation was evaluated against induced infections of developing fourth-stage larval or adult gastrointestinal and pulmonary nematodes of cattle in a series of six studies under two identical protocols (three each for developing fourth-stage larvae or adults) conducted in the USA, Germany or the UK (two studies at each location, one per stage). Each study initially included 16 nematode-free cattle. The cattle were of various breeds or crosses, weighed 109-186.5 kg prior to treatment, and were approximately 4-7 months old. The animals were blocked based on pre-treatment bodyweight and then randomly allocated to treatment: eprinomectin ER! vehicle (control) at 1 mL/50 kg body weight or eprinomectin 5% ER! at 1 mL/50 kg bodyweight (1.0 mg eprinomectin/kg) for a total of eight and eight animals in each group. Treatments were administered once on Day 0 by subcutaneous injection in front of the shoulder. In each study, cattle were infected with a combination of infective third-stage larvae or eggs of gastrointestinal and pulmonary nematodes. Inoculation was scheduled so that the nematodes were expected to be fourth-stage larvae or adults at the time of treatment. For parasite recovery, all study animals were humanely euthanized and necropsied 14-15 (adult infections) or 21-22 days after treatment (developing fourth-stage larval infections). When compared with the vehicle-treated control counts, efficacy of eprinomectin ERI against developing fourth-stage larvae and adults was >= 98% (p <0.05) for the following nematodes: Dictyocaulus viviparus, Bunostomum phlebotomum, Cooperia curticei, C oncophora, C surnabada, C. punctata, Haemonchus contortus, H. placei, Nematodirus helvetianus, Oesophagostomum radiatum, Oes. venutosum, Ostertagia leptospicularis, O. ostertagi, O. circumcincta, O. pinnata, O. trifurcata (developing fourth-stage larval infections only), Strongyloides papillosus, Trichostrongylus axei, T. colubnformis, and Trichuris ovis (adult infections only). All animals accepted the treatment well. No adverse reaction to treatments was observed in any animal in any study
机译:在两项相同的方案下进行的六项研究中,评估了依普利菌素在缓释注射液(ERI)制剂中对发展中的牛第四阶段幼虫或成年胃肠道和肺线虫的诱发感染的治疗效果(三项针对第四项发展)阶段的幼虫或成年幼虫在美国,德国或英国进行(每个地点进行两项研究,每个阶段进行一项研究)。每个研究最初都包括16只无线虫的牛。这些牛有不同的品种或杂交,在治疗前重109-186.5公斤,大约4-7个月大。根据治疗前体重对动物进行阻滞,然后将其随机分配至治疗:依普连菌素ER! 1毫升/ 50公斤体重的载体(对照)或表皮生长素5%ER!每组体重分别为1毫升/ 50千克体重(1.0毫克依诺菌素/千克),共八和八只动物。在第0天通过在肩前皮下注射进行一次治疗。在每项研究中,牛均感染了感染性第三阶段幼虫或胃肠道和肺线虫的卵。安排了接种时间,以便在治疗时预期线虫是第四阶段的幼虫或成虫。为了进行寄生虫恢复,对所有研究动物进行人道安乐死并在治疗后14-15(成人感染)或21-22天(进行第四阶段幼虫感染)进行尸检。与媒介物处理的对照计数相比,对于以下线虫,依普连菌素ERI对抗发育中的第四阶段幼虫和成虫的功效> = 98%(p <0.05):ic线虫,食肉牛膝,库珀木贼,C oncophora,C surnabada,C。punctata,Haemonchus contortus,H.placei,Nematodirus helvetianus,Oesophagostomum radiatum,Oes。 venutosum,Ostertagia leptospicularis,O.ostertagi,O.circumcincta,O.pinnata,O.trifurcata(仅发展为第四阶段幼虫感染),Strongyloides papillosus,Trichostrongylus axei,T.colubnformis和Trichuris ovis(仅成人感染)。所有动物都很好地接受了治疗。在任何研究中,任何动物均未观察到对治疗的不良反应

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号